The standard of treatment for macular neovascularisation (MNV) secondary to neovascular age related macular degeneration (nAMD) is intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents [1]. Here, VEGFA is linked to wet macular degeneration.